Geneesmiddelen | Horizonscan geneesmiddelen

AR101 Olopatadine / mometasone Pinda extract

Andexanet alfa Betrixaban Dabigatran etexilaat ^IND Ravulizumab ^IND Rivaroxaban ^IND

Dupilumab ^IND Fluticasone furoate / umeclidinium / vilanterol ^IND Indacaterol acetate/glycopyrronium bromide/mometasone furoate Indacaterol acetate/mometasone furoate

Omalizumab

Aanvullende behandeling om de astmacontrole te verbeteren bij patiënten met ernstig persistent allergisch astma. ^BS Aanvullende behandeling om de astmacontrole te verbeteren bij patiënten met ernstig persistent allergisch astma. ^BS Aanvullende behandeling om de astmacontrole te verbeteren bij patiënten met ernstig persistent allergisch astma. Ook voor de behandeling van chronische idiopathische urticaria. ^BS

Tezepelumab Tiotropium ^IND

Amoxicilline / omeprazol / rifabutin Cefiderocol Ceftolozaan / tazobactam ^IND Delafloxacin (meglumine) Eravacycline Iclaprim Imipenem / Relebactam Lefamulin Liposomaal amikacine Meropenem / vaborbactam Omadacycline Ozenoxacine Plazomicin Tedizolid ^IND Tigecycline ^G

Atezolizumab ^IND Pembrolizumab ^IND Ramucirumab ^IND

Alicaforsen Darvadstrocel Remestemcel-L ^IND Tenapanor Tofacitinib ^IND Ustekinumab ^IND

Depatuxizumab mafodotin

Abemaciclib Alpelisib Atezolizumab ^IND Neratinib Olaparib ^IND

Pembrolizumab

Breast cancer, metastatic, triple negative, 1L. ^IND 2/3L Triple negative metastatic breast cancer ^IND Triple Negative Breast Cancer - Neoadjuvant ^IND

Ribociclib

Behandeling van HR+/HER2- lokaal gevorderd of gemetastaseerd mammacarcinoom in combinatie met een aromataseremmer of fulvestrant. In pre- of perimenopauzale vrouwen dient de endocriene therapie gecombineerd te worden met een ‘luteinizing hormone-releasing hormone’ (LHRH) agonist. ^IND Breast cancer, advanced metastatic, HR+ and HER2-, in combination with fulvestrant, postmenopausal women and men, 1L en 2L. ^IND

Talazoparib Trastuzumab emtansine ^IND Veliparib

Beclometasone dipropionate / formoterol fumarate dihydrate / glycopyrronium ^IND Benralizumab ^IND Fluticasone furoate / umeclidinium / vilanterol ^IND Formoterol / glycopyronium / budesonide Formoterol/glycopyronium Mepolizumab Revefenacin

Apremilast ^IND Avacopan Rituximab ^IND

Axalimogene filolisbac

Atezolizumab ^IND Encorafenib ^IND

Ivacaftor

Kalydeco granules are indicated for the treatment of children with cystic fibrosis (CF) aged 12-24 months and weighing 7 kg to less than 25 kg who have one of the following gating (class III) mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R ^IND Cystische fibrose voor kinderen van 6 tot 12 maanden met een gating mutatie. ^IND Kalydeco tablets are indicated in a combination regimen with tezacaftor 100 mg/ivacaftor 150 mg tablets for the treatment of patients with cystic fibrosis (CF) aged 12 years and older who are homozygous for the F508del mutation or who are heterozygous for the F508del mutation and have one of the following mutations in the CFTR gene: P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272-26A→G, and 3849+10kbC→T.

Lumacaftor / ivacaftor ^IND

Tezacaftor / ivacaftor

Symkevi is indicated in a combination regimen with ivacaftor 150 mg tablets for the treatment of patients with cystic fibrosis (CF) aged 12 years and older who are homozygous for the F508del mutation or who are heterozygous for the F508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272-26A→G, and 3849+10kbC→T. Cystische fibrose voor patiënten van 6 tot en met 11 jaar met met een dubbele F508del-mutatie of één F508del plus één van de volgende 14 mutaties: P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272-26A→G, 3849+10kbC→T. ^IND

Leuco-methylthioninium

Alzheimer’s disease, mild-to-moderate. Dementia, behavioural variant frontotemporal.

Canagliflozin ^IND Dapagliflozin / saxagliptin / metformin Dapagliflozine ^IND Dasiglucagon Empagliflozine ^IND Ertugliflozin Ertugliflozin / metformin Ertugliflozin / sitagliptin

Exenatide

Diabetes type 2 Bydureon is a diabetes medicine used together with other diabetes medicines including long-acting insulin to treat adults with type 2 diabetes whose blood glucose (sugar) levels are not adequately controlled with the other medicines

Finerenone Glucagon Insuline voor inhalatie Reparixin Semaglutide Sotagliflozin

Cannabidiol Fenfluramine Vigabatrin

Abicipar Aflibercept ^BS Aganirsen Brolucizumab Cenegermin Ciclosporin Eculizumab ^IND Fluocinolone acetonide ^IND Latanoprostene bunod Lenadogene nolparvovec Lifitegrast Netarsudil mesylate Polihexanide

Ranibizumab

Wet age-related macular degeneration (AMD). ^BS Wet age-related macular degeneration (AMD). ^BS Wet age-related macular degeneration (AMD). ^BS Wet age-related macular degeneration (AMD). ^BS

Reproxalap Voretigene neparvovec

Itacitinib Remestemcel-L

Durvalumab / Tremelimumab

Head and neck (or upper airways tract) cancers; squamous cell carcinoma of head or neck (SCCHN), 2L Durvalumab monotherapy in PDL1-positive tumours or in combination with Tremelimumab for PDL1-negative tumours. Squamous cell carcinoma of the head and neck, 1L PDL 1 ^IND

Pembrolizumab

Keytruda as monotherapy is indicated for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD-L1 with a ≥ 50% TPS and progressing on or after platinum-containing chemotherapy. (2L) ^IND 1L squamous head and neck cancer with PD-L1 expression. ^IND

Eptinezumab Erenumab Fremanezumab

Galcanezumab

Emgality is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month. Clusterhoofdpijn ^IND

Lasmiditan

Donor-derived T-lymphocyte enriched leukocyte preparation depleted ex vivo of host-alloreactive T cells.

Fedratinib

Myelofibrosis Polycythemia vera ^IND

Fostamatinib Lusutrombopag Pacritinib Ropeginterferon alfa-2b Treosulfan

Damoctocog alfa pegol Emicizumab ^IND Eptacog alfa (activated) ^IND Eptacog beta (activated) Turoctocog alfa pegol Valoctocogene roxaparvovec (BMN 270) Vonicog alfa

Abaloparatide Levoketoconazole Macimorelin Osilodrostat Prasterone Recombinant parathyroid hormone Tenapanor ^IND

Atezolizumab ^IND Avelumab ^IND Ipilimumab ^IND Pembrolizumab ^IND Rocapuldencel-T Sunitinib ^IND

Blinatumomab

Blincyto is indicated as monotherapy for the treatment of adults with Philadelphia chromosome negative CD19 positive B-precursor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%. ^IND Monotherapy for the treatment of paediatric patients aged 1 year or older with Philadelphia chromosome negative CD19 positive B-cell precursor ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplantation. ^IND Relapsed / Refractory Ph+ Adult Acute Lymphoblastic Leukemia (ALL). ^IND

Cytarabine / daunorubicin (liposomaal)

Dasatinib

Geïndiceerd voor de behandeling van pediatrische patiënten met nieuw gediagnosticeerde Ph+ CML in de chronische fase (Ph+ CML-CP) of met Ph+ CML-CP die resistent of intolerant zijn voor eerder toegediende geneesmiddelen waaronder imatinib. ^IND Extension of Indication to include a paediatric indication for Philadelphia chromosome positive acute lymphoblastic leukaemia for Sprycel. ^IND

Duvelisib Enasidenib Eryaspase (Asparaginase) Gemtuzumab ozogamicin Gilteritinib

Ibrutinib

1L Chronic Lymphatic Leukemia young and fit patients ^IND Extension of indication to the existing chronic lymphocytic leukaemia (CLL) indication to include combination use with obinutuzumab for the treatment of adult patients with previously untreated CLL. ^IND

Imetelstat Luspatercept Moxetumomab pasudotox Quizartinib Sapacitabine Tisagenlecleucel-T Venetoclax ^IND Venetoclax in combinatie met rituximab ^IND

Alirocumab ^IND Bempedoic acid Inclisiran Volanesorsen (sodium)

Cabozantinib ^IND Lenvatinib ^IND Nivolumab ^IND Ramucirumab ^IND

Cenicriviroc Obeticholic acid

Atezolizumab

1L gemetastaseerd niet-plaveisecel NSCLC icm bevacizumab en chemotherapie ^IND For the 1L treatment of patients with metastatic, squamous NSCLC in combination with chemotherapy ^IND Extensive-stage small-cell lung cancer, first-line treatment in combination with carboplatin and etoposide. Independent of PD-L1 expression. ^IND

Brigatinib Dacomitinib Durvalumab Durvalumab / Tremelimumab ^IND Entrectinib Lorlatinib Lurbinectedin Nivolumab ^IND Osimertinib ^IND

Pembrolizumab

First-line treatment of metastatic non-squamous NSCLC in adults whose tumours have no EGFR or ALK positive mutations in combination with pemetrexed and platinum chemotherapy. ^IND Extension of Indication to include, in combination with carboplatin and either paclitaxel or nab-paclitaxel, for the first-line treatment of metastatic squamous NSCLC in adults for Keytruda. ^IND Gevorderd (stadium IIIb) of gemetastaseerd 1L NSCLC, ALK-/EGFR- (monotherapie, met een PD-L1 expressie >1%) ^IND

Rociletinib Rovalpituzumab tesirine Veliparib

Axicabtagene ciloleucel Brentuximab vedotin ^IND

Ibrutinib

Follicular lymphoma (FL), relapsed / refractory. ^IND Mantle cell lymphoma (MCL), 1L. ^IND Marginal zone lymphoma (MZL), relapsed / refractory. ^IND Non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma (DLBCL), 1L. ^IND Extension of indication to include treatment of adult patients with Waldenström's macroglobulinaemia (WM) in combination with rituximab. ^IND

Lenalidomide

Relapsed/refractory follicular lymphoma (FL) en marginal zone lymphoma (MZL) in combinatie met rituximab ^IND 1e lijn ABC subtype DLBCL in combinatie met rituximab en CHOP ^IND

Lisocabtagene maraleucel Mogamulizumab Plerixafor ^IND Polatuzumab vedotin Tisagenlecleucel-T

Nivolumab ^IND

Arimoclomol citraat Asfotase alfa Burosumab Cerliponase alfa Chenodeoxycholzuur Cyclodextrine (Hydroxypropyl betadex) Idursulfase-IT Kaliumcitraat / kaliumwaterstofcarbonaat Metreleptin Patiromer Pegvaliase Sodium zirconium cyclosilicate TRC101 Trientine Velmanase alfa Vestronidase alfa

Daratumumab

Darzalex is indicated in combination with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. ^IND Multipel myeloom frontline behandeling in combinatie met Rd voor patienten die niet in aanmerking komen voor een ASCT. ^IND Multipel myeloom frontline behandeling in combinatie met VTd fit voor ASCT. ^IND

Elotuzumab ^IND GSK2857916 Isatuximab Lenalidomide ^IND Pomalidomide / bortezomib / dexamethason ^IND

Fingolimod ^IND Masitinib Ozanimod Siponimod

AMDC-USR

Botulinum A toxin

Lower limb spasticity (LLS), in adults post stroke or traumatic brain injury (TBI). ^IND Treatment of adult patients with glabellar lines, also known as "frown lines" between the eyebrows.

Edaravone Eteplirsen Mexiletine HCl Nusinersen Onasemnogene abeparvovec

L-lysine / L-arginine Lutetium (177Lu) oxodotreotide Selumetinib Telotristat etiprate

Abatacept ^IND Budesonide Elobixibat Emapalumab Forigerimod Lanadelumab Lesinurad / allopurinol Naldemedine Teprasiran Teprotumumab

Tocilizumab

Systemische Sclerose ^IND Voor de behandeling van ernstige of levensbedreigende cytokine-release syndrome (CRS) geïnduceerd door chimerische antigeenreceptor (CAR) T-cellen bij volwassenen en kinderen van 2 jaar en ouder. ^IND

Triamcinolone

Isavuconazole Posaconazole ^G

Ambrisentan

Behandeling van pulmonale arteriële hypertensie (PAH) bij volwassen patiënten geclassificeerd als WHO functionele klasse (FC) II of III, waaronder gebruik in een combinatietherapie. ^G Behandeling van pulmonale arteriële hypertensie (PAH) bij volwassen patiënten geclassificeerd als WHO functionele klasse (FC) II of III, waaronder gebruik in een combinatietherapie. ^G

Ciprofloxacin Mepolizumab ^IND

Nintedanib

Systemic Sclerosis - Interstitial Lung Disease (SSc-ILD) ^IND Treatment of Progressive Fibrosing Interstitial Lung Disease (PF-ILD) ^IND

Sarizotan Sirolimus ^IND

Angiotensin II Canakinumab ^IND Dapagliflozine ^IND Tafamidis ^IND Ticagrelor ^IND Treprostinil Valsartan / sacubitril ^IND

Nolasiban Romosozumab

Botulinum A toxin ^IND Brimapitide Buprenorphine Inotersen Natriumoxybaat Patisiran Ronopterin

Autologous CD34+ cell enriched population that contains hematopoietic stem cells transduced with lentiglobin bb305 lentiviral vector encoding the beta-a-t87q-globin gene Avatrombopag Caplacizumab

Deferasirox

Eculizumab

Paroxysmal nocturnal haemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) ^BS Paroxysmal nocturnal haemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) ^BS Paroxysmal nocturnal haemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). ^BS

Eltrombopag ^IND Ferumoxytol Hydroxycarbamide ^G L-Glutamine Ravulizumab Roxadustat

Entolimod Entrectinib Erlotinib ^G Larotrectinib

Pembrolizumab

Unresectable or metastatic solid tumours with a microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) biomarker. ^IND 2L advanced esophageal cancer, squamous ^IND

Pexidartinib

Avelumab ^IND

Olaparib

Lynparza is geïndiceerd als monotherapie voor de onderhoudsbehandeling van volwassen patiënten met platinasensitief recidief hooggradig epitheliaal ovarium, tuba- of primair peritoneaal carcinoom die een respons (volledige of partiële) vertonen op platinabevattende chemotherapie. Extension of indication to include the use of Lynparza as a montherapy for the maintenance treatment of adult patients with newly diagnosed advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy. ^IND

Paclitaxel Rucaparib Veliparib

Neridronic Acid

Olaparib ^IND

Apomorphine Ioflupane (123I) ^G Levodopa Pimavanserin

Abiraterone / apalutamide

Apalutamide

Gemetastaseerde hormoon-gevoelige, hoog-volume prostaat carcinoom. ^IND Niet-gemetastaseerde castratie resistente prostaat carcinoom (hoog risico).

Cabazitaxel ^G Darolutamide

Enzalutamide

Adult men with newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in combination with androgen depreviation therapy. ^IND De behandeling van volwassen mannen met niet-gemetastaseerd hoogrisico-CRPC (castratieresistent prostaatcarcinoom). ^IND

Padeliporfin

Brexanolone Brexpiprazole Cariprazine

Esketamine

Treatment resistant depression (Major Depressive Disorder in adults who have not responded to at least two different treatments with antidepressants in the current moderate to severe depressive episode) Major Depressive Disorder with imminent risk of suicide ^IND

Lurasidone ^IND

Abatacept ^IND Filgotinib Ixekizumab ^IND Olokizumab Secukinumab ^IND

Tocilizumab

Rheumatoid arthritis (RA), giant lymph node hyperplasia (Castlesman’s disease), polyarticular idioathic juvenile arthritis (PJIA) and systemic juvenile idiopathic arthritis (SJIA). ^BS RoActemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 1 year of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. RoActemra can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX. ^IND

Tofacitinib ^IND Upadacitinib

Cemiplimab Dabrafenib / Trametinib ^IND Encorafenib Lifileucel Nivolumab ^IND Pembrolizumab ^IND Seviprotimut-L

Certolizumab pegol ^IND Clascoterone Crisaborole Dupilumab ^IND Glycopyrronium tosylate KX2-391 Risankizumab Rituximab ^IND Tildrakizumab Ustekinumab ^IND

Lemborexant Melatonin Natriumoxybaat ^IND Pitolisant ^IND Solriamfetol Tasimelteon ^IND

Masitinib Nivolumab ^IND Pembrolizumab ^IND Trifluridine / tipiracil ^IND

Selumetinib ^IND

Regadenoson ^IND

Baloxavir marboxil Bictegravir / emtricitabine / tenofovir alafenamide fumaraat Cabotegravir / Rilpivirine Dolutegravir / lamivudine Dolutegravir / rilpivirine Doravirine Doravirine / lamivudine / tenofovir disoproxil (fumarate) Fostemsavir Ibalizumab Letermovir Sofosbuvir / velpatasvir / voxilaprevir Zanamivir

Informatie over geneesmiddelen die in de nabije toekomst op de markt verwacht worden.

Published on 13 December 2018

Allergy

Antithrombotic medications

Asthma

Omalizumab

Bacterial infections

Bladder cancer

Bowel diseases

Brain cancer

Breast cancer

Pembrolizumab

Ribociclib

COPD

Cardiovascular diseases

Cervical cancer

Colon cancer

Cystic fibrosis

Ivacaftor

Tezacaftor / ivacaftor

Dementia

Leuco-methylthioninium

Diabetes

Exenatide

Epilepsy

Eye disorders

Ranibizumab

Graft versus Host

Head and neck cancer

Durvalumab / Tremelimumab

Pembrolizumab

Headache

Galcanezumab

Hematology other

Fedratinib

Hemostasis promoting medication

Hormonal disorders

Kidney cancer

Leukemia

Blinatumomab

Dasatinib

Ibrutinib

Lipid-lowering medications

Liver cancer

Liver diseases

Lung cancer

Atezolizumab

Pembrolizumab

Lymphoma

Ibrutinib

Lenalidomide

Mesothelioma

Metabolic diseases

Multiple Myeloma

Daratumumab

Multiple sclerosis

Muscular diseases

Botulinum A toxin

Neuroendocrine cancer

Other chronic immune diseases

Tocilizumab

Other infectious diseases

Other lung

Ambrisentan

Nintedanib

Other medication for cardiovascular diseases

Other metabolism and Endocrinology

Other neurological disorders

Other non-oncological hematological medications

Deferasirox

Eculizumab

Other oncology

Pembrolizumab

Ovarian cancer

Olaparib

Pain

Pancreatic cancer

Parkinson's

Prostate cancer

Apalutamide